ReviewDiscover oncology2026
Roles of tumor associated neutrophils in the development of hepatocellular carcinoma and therapeutic implications.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death globally, with limited clinical response to conventional therapies and emerging immune checkpoint inhibitors, such as Programmed death receptor-1/programmed death receptor ligand-1 (PD-1/PD-L1) antibodies. In recent years, immunomodulatory cells in the tumor microenvironment (TME) have become a focus of research. Among these, tumor-associated neutrophils (TANs) have been found to play a key role in HCC progression by modulating immune suppression, promoting angiogenesis and facilitating tumor metastasis. Although the role of TANs in various cancers has been extensively studied, systematic reviews on their heterogeneous functions and regulatory mechanisms in HCC remain scarce, and existing studies have yet to comprehensively integrate targeted therapeutic strategies. Therefore, this review aims to fill this research gap by systematically summarizing the current advancements in understanding the origin and functional roles of TANs in HCC, while emphasizing emerging TANs-centered therapeutic strategies to improve immune treatment efficacy and achieve more precise interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.